Oxford BioTherapeutics Rating A · Worker

Oxford BioTherapeutics is a clinical-stage oncology company that develops targeted cancer therapies. The business focuses on pioneering treatments such as antibody-drug conjugates, immuno-oncology therapies, t-cell engagers, and radiopharmaceuticals to improve outcomes for cancer patients globally.

The company utilises its proprietary database, which contains thousands of identified and quantified membrane proteins, to discover novel targets for antibody-based therapeutics. Through research and development sites, the firm analyses patient tissue, shortlists cancer-specific targets, and generates therapeutic antibodies and binders in partnership with other innovators in the healthcare sector.